Drug Name: Daxxify
Active Ingredient: daxibotulinumtoixnA-lanm
Indications: To treat moderate-to-severe glabellar lines associated with corrugator and/or procerus muscle activity.
Approval Date: 9/7/2022
Company: Revance Therapeutics, Inc
Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761127s000lbl.pdf